Trioxifene mesylate

LW (male, 110-125 g, injected s.c. with 1×10⁶ PAIII prostatic adenocarcinoma cells in the dorsal tail)^[2]

2.0 mg/kg; 4.0 mg/kg; 20.0 mg/kg; 40.0 mg/kg

s.c.; daily; 28 days or continuously until death

Produced significant (P < 0.05) inhibition of PAIII metastasis, with maximum 86% reduction in gluteal lymph node weight, 88% reduction in iliac lymph node weight, and 98% reduction in pulmonary foci count at 40.0 mg/kg-day for 28 days.
Did not reduce primary tail tumor weight at any dose.
Induced dose-related, significant (P < 0.05) regression of male accessory sex organs, with maximum 76% reduction in normalized ventral prostate weight and 64% reduction in normalized seminal vesicle weight at 40.0 mg/kg-day for 28 days.
Caused significant (P < 0.05) dose-related decreases in final-to-initial body weight ratios, with a maximum 31% reduction at 40.0 mg/kg-day for 28 days.
Increased normalized testicular weights significantly (P < 0.05), though absolute testicular weights did not differ from controls.
Extended mean survival to 50.11 days in rats treated with 40.0 mg/kg-day for 28 days followed by vehicle, significantly longer than vehicle controls (41.78 days).
Extended mean survival to 64.44 days in rats treated continuously with 40.0 mg/kg-day until death, significantly longer than both vehicle controls and the 28-day treatment group.